Core Viewpoint - The financial performance of Keta Bio (300858) for the first half of 2025 shows an increase in total revenue but a decline in net profit, indicating mixed results in operational efficiency and profitability [1]. Financial Performance Summary - Total revenue for the first half of 2025 reached 163 million yuan, a year-on-year increase of 18.32% compared to 138 million yuan in 2024 [1]. - Net profit attributable to shareholders was 41.21 million yuan, down 5.31% from 43.51 million yuan in the previous year [1]. - The gross profit margin decreased to 49.24%, a decline of 10.44% year-on-year, while the net profit margin fell to 25.23%, down 19.97% [1]. - The company reported a significant increase in accounts receivable, which reached 69.07 million yuan, up 23.88% from 55.58 million yuan [1]. - Operating cash flow per share decreased by 44.47% to 0.11 yuan, compared to 0.19 yuan in the previous year [1]. Cost and Expense Analysis - Total expenses (selling, administrative, and financial) amounted to 17.93 million yuan, accounting for 10.98% of revenue, which is a decrease of 7.62% year-on-year [1]. - The increase in operating costs was attributed to a 33.41% rise in costs related to the production base for animal and plant micro-ecological agents [2]. Investment and Financing Activities - The net cash flow from financing activities increased by 97.49%, primarily due to dividend distributions in the previous year [3]. - The company has seen a 73.69% increase in construction in progress, reflecting investments in the food sector's research and production base [2]. Market and Business Model Insights - The company's return on invested capital (ROIC) was reported at 3.95%, indicating weak capital returns, while the historical median ROIC since listing is 12.39% [3]. - Analysts project that the company's performance for 2025 will reach approximately 128 million yuan, with an average earnings per share of 0.49 yuan [3].

北京市东城区 北三环东路 36 号环球贸易中 心 B 座 11 层 电话（Tel）： 52213236/7 邮编（P.C）： 100013 关 于 北 京 科 拓 恒 通 生 物 技 术 股 份 有 限 公 司 2024 年 限 制 性 股 票 激 励 计 划 授 予 价 格 调 整 事 项 的 法 律 意 见 书 君致法字[2025]226 号 北 京 市 君 致 律 师 事 务 所 北京市东城区北三环东路 36 号环球贸易中心 B 座 11 层 邮编(100013) Add:11/F,Tower B,Global Trade Center,No.36 North Third Ring Road East, Dongcheng District,Beijing,100013,PRC Tel:010-52213236/7 www.junzhilawyer.com 法律意见书 北京市君致律师事务所 关于北京科拓恒通生物技术股份有限公司 2024 年限制性股票激励计划授予价格调整事项的 法律意见书 君致法字[2025]226 号 致：北京科拓恒通生物技术股份有限公司 北京市君致律师事务所（以下简称"本所"）接受北 ...

证券代码：300858 证券简称：科拓生物 公告编号：2025-032 4、2024 年 4 月 8 日，公司召开 2024 年第一次临时股东大会，审议通过了 《关于<北京科拓恒通生物技术股份有限公司 2024 年限制性股票激励计划（草 案）>及其摘要的议案》《关于<北京科拓恒通生物技术股份有限公司 2024 年限 制性股票激励计划实施考核管理办法>的议案》《关于提请股东大会授权董事会办 理 2024 年限制性股票激励计划相关事宜的议案》，关联股东已回避表决，同时公 司披露了《关于 2024 年限制性股票激励计划内幕信息知情人及激励对象买卖公 司股票情况的自查报告》。 北京科拓恒通生物技术股份有限公司 关于调整 2024 年限制性股票激励计划授予价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京科拓恒通生物技术股份有限公司（以下简称"公司"）于 2025 年 8 月 18 日召开的第三届董事会第十四次会议、第三届监事会第十三次会议，审议通 过了《关于调整 2024 年限制性股票激励计划授予价格的议案》。现将相关内容 公告如下： 一、2024 年限 ...

Group 1 - The core viewpoint of the report indicates that Keta Bio achieved a revenue of 163.35 million yuan in the first half of 2025, representing an 18.32% increase year-on-year, while the net profit attributable to shareholders decreased by 5.31% to 41.21 million yuan [1] - The net cash flow from operating activities was 27.88 million yuan, showing a significant decline of 44.47% compared to the previous year [1] - Research and development investment amounted to 16.74 million yuan, reflecting a year-on-year growth of 4.25% [1] Group 2 - Keta Bio strategically invested 20 million yuan in Qinghe Shixiang, acquiring a 7.14% stake to develop ready-to-eat probiotic products for teenagers, aiming to expand the ToC probiotic market [2] - The company established an overseas division to actively explore international markets and participated in the European International Nutrition and Health Food Exhibition to showcase the research progress and application value of "Chinese bacteria" [2] - The food sector's R&D production base Phase I project is progressing smoothly, with major construction completed and trial production expected to commence within 2025 [2] Group 3 - As of June 30, 2025, Keta Bio's total assets reached 1.94 billion yuan, a 1.46% increase from the end of the previous year, while the net assets attributable to shareholders grew by 0.09% to 1.79 billion yuan, indicating stable overall financial conditions [2]

Core Viewpoint - The company reported revenue growth in the first half of 2025 but experienced a decline in profit, indicating potential challenges in maintaining profitability despite increasing sales [1][3]. Financial Performance - The company achieved an operating revenue of 163 million yuan, representing a year-on-year increase of 18.32% [1]. - The net profit attributable to shareholders was 41 million yuan, reflecting a year-on-year decrease of 5.31% [1]. - The net profit margin decreased from 31.52% in the first half of 2024 to 25.23% in 2025, a decline of 6.30 percentage points [3]. - The gross profit margin fell from 54.98% to 49.24%, a decrease of 5.74 percentage points [3]. - The return on equity was 2.28%, down by 0.20 percentage points compared to the previous year [3]. Operational Efficiency - The company faced cash flow contraction, with net cash flow from operating activities amounting to 28 million yuan, down from 50 million yuan in the same period last year, a decline of 22 million yuan [5]. - Inventory turnover days improved to 98.42 days, a decrease of 8.48% compared to the first half of 2024, indicating better inventory management [5]. - The asset-liability ratio increased to 7.84%, up by 3.37 percentage points year-on-year [5]. Institutional Holdings - The number of institutional investors holding the company's stock decreased to 3, down from 43 in the same period last year, indicating a loss of confidence among institutional investors [7]. - The company's market capitalization reached a peak of 8.511 billion yuan on August 17, 2020, and currently stands at 5.312 billion yuan, requiring a 60.22% increase in stock price to reach its historical high [7]. - The stock price has increased by 41.47% year-to-date, suggesting some recovery [7].

证券日报网讯 8月19日晚间，科拓生物发布公告称，公司于2025年8月18日召开的第三届董事会第十四 次会议和第三届监事会第十三次会议，审议通过《关于续聘2025年度审计机构的议案》，拟续聘中审众 环会计师事务所（特殊普通合伙）作为公司2025年度财务报表及内部控制审计机构。 （文章来源：证券日报） ...

格隆汇8月19日丨科拓生物(300858.SZ)公布2025年半年度报告，上半年公司实现营业收入1.63亿元，同 比增长18.32%；归属于上市公司股东的净利润4120.51万元，同比下降5.31%；归属于上市公司股东的扣 除非经常性损益的净利润3512.69万元，同比下降6.67%；基本每股收益0.16元。 ...

Core Viewpoint - Keta Bio announced the receipt of five patent certificates from the National Intellectual Property Administration, indicating a focus on innovation in the biotechnology sector [3]. Group 1: Company Developments - Keta Bio's revenue composition for the year 2024 is entirely from the food manufacturing industry, with a 100.0% share [1]. - The company has received five patents related to probiotic compositions and methods, which may enhance its product offerings and market position [3]. Group 2: Patent Details - The patents include "Probiotic Postbiotics Composition for Improving Scalp Environment and Its Preparation Method and Application" and "Low Sodium, Reduced Salt Flavor Enhancer Postbiotics and Its Preparation Method and Application" [3].

Core Viewpoint - The company reported a year-on-year increase in revenue for the first half of 2025, but a decline in net profit and earnings per share [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 163 million yuan, representing an 18.32% increase compared to the previous year [2] - The net profit attributable to shareholders was around 41.21 million yuan, which is a decrease of 5.31% year-on-year [2] - Basic earnings per share were 0.16 yuan, reflecting a decline of 5.88% compared to the same period last year [2]

北京科拓恒通生物技术股份有限公司 董事、高级管理人员所持本公司股份及其变动管理制度 第一章 总则 第一条 为了进一步加强北京科拓恒通生物技术股份有限公司（以下简称"公 司"或"本公司"）董事、高级管理人员持有本公司股份及其变动行为的管理， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）、《上市公司董事和高级管理人员所持 本公司股份及其变动管理规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关法律法规、规范性文件的相关要求，以 及《北京科拓恒通生物技术股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，结合本公司实际情况，制定本制度。 第二条 本制度适用于公司董事、高级管理人员及本制度第七条规定的自然 人、法人或其他组织所持本公司股份及其变动行为的管理。 第三条 公司董事、高级管理人员所持本公司股份，是指登记在其名下和利 用他人账户持有的所有本公司股份。上述人员从事融资融券交易的，其所持本公 司股份还包括记载在其信用账户内的本公司股份。 第四条 公司董事、高级管理人员在买卖本公司股票及其衍生品种前，应知 悉 ...